2018
Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy
Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.Peer-Reviewed Original ResearchConceptsVaginal stenosisEndometrial carcinomaMultivariable Cox proportional hazardsMultivariable Cox regression analysisVD useAcademic tertiary referral centerTertiary referral centerCox regression analysisLog-rank testCox proportional hazardsDevelopment of gradeDilator usePelvic radiotherapyReferral centerNoncompliant patientsPrimary outcomeAdjuvant brachytherapyEC patientsConclusionsThe riskRate brachytherapyProportional hazardsOptimal durationPatientsBrachytherapyStudy period
2015
Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation
Rutter CE, Park HS, Corso CD, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Lung Cancer 2015, 90: 243-248. PMID: 26277031, DOI: 10.1016/j.lungcan.2015.08.002.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerDose-fractionation regimensLimited-stage small cell lung cancerConcurrent CRTConcurrent chemoradiationOverall survivalLimited-stage small-cell lung cancer patientsProportional hazardsSmall cell lung cancer patientsMultivariable Cox proportional hazardsCell lung cancer patientsOptimal radiotherapy doseOngoing randomized trialsInferior overall survivalKaplan-Meier analysisCell lung cancerLarger tumor sizeMedian survival timeLung cancer patientsCox proportional hazardsStandard radiotherapy regimensLarge national datasetChemoradiation regimensSimilar OSEquivalent OSAngiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy
Harder EM, Park HS, Nath SK, Mancini BR, Decker RH. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy. Practical Radiation Oncology 2015, 5: e643-e649. PMID: 26412341, DOI: 10.1016/j.prro.2015.07.003.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyACE inhibitor useNonsteroidal anti-inflammatory drugsAngiotensin receptor blockersRadiation pneumonitisSymptomatic radiation pneumonitisInhibitor useBody radiation therapyAnti-inflammatory drugsRadiation therapyReceptor blockersACE inhibitorsAngiotensin-converting enzyme inhibitor useACE inhibitor usersCommon Terminology CriteriaEnzyme inhibitor usePrimary lung cancerNormal lung tissuesAvailable medical recordsCox proportional hazardsPulmonary doseTerminology CriteriaInhibitor usersAdverse eventsOverall survival